

*Clinical and Economic Considerations of Coronary Heart Disease:
A Managed Care Approach*

Proceedings in this Special Report supplement to *The American Journal of Managed Care* are based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, hosted by Bristol-Myers Squibb, November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, hosted by the International Society for Pharmacoeconomics and Outcomes Research (formerly known as the Association for Pharmacoeconomics and Outcomes Research) November 5-7, 1997 in Orlando, Florida.

The proceedings in this Special Report supplement have been reviewed by Simeon Margolis, MD, PhD, Professor of Medicine and Biological Chemistry, Division of Endocrinology & Metabolism, Johns Hopkins University School of Medicine.

PRESENTERS

Susan Andrade, ScD

Assistant Professor of Pharmacoepidemiology
Department of Applied Pharmaceutical Sciences
University of Rhode Island
Kingston, Rhode Island

John S. Banas, Jr., MD, FACC

Professor of Clinical Medicine
College of Physicians and Surgeons
Columbia University
New York, New York
Chairman, Department of Cardiovascular Medicine
Morristown Memorial Hospital
Morristown, New Jersey

James C. Bonnette, MD

Medical Director, Disease Management
Integrated Pharmaceutical Services
Fair Oaks, California

W. Virgil Brown, MD

Chief, Division of Arteriosclerosis & Lipid Medicine
Emory University School of Medicine
Atlanta, Georgia

William P. Castelli, MD

Medical Director
Framingham Cardiovascular Institute
Columbia MetroWest Medical Center
Framingham, Massachusetts

Stuart M. Cobbe, MD, FRCP

Walton Professor of Medical Cardiology
Department of Medical Cardiology
Glasgow Royal Infirmary
Glasgow University
Glasgow, Scotland

Peter Davey, MD, FRCP

Reader in Clinical Pharmacology &
Infectious Disease
University of Dundee
Ninewells Hospital & Medical School
Dundee, Scotland

Joel W. Hay, PhD

Associate Professor
University of Southern California
Department of Pharmaceutical Economics and
Policy
Los Angeles, California

Bruce Kinosian, MD

Associate Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Paul C. Langley, PhD

Professor
School of Pharmacy
University of Colorado
Denver, Colorado

Grant D. Lawless, MD, RPh
Vice President of Medical and Pharmacy Affairs
Highmark BlueCross and BlueShield
Pittsburgh, Pennsylvania

William F. McGhan, PharmD, PhD
Professor of Pharmacy
Department of Pharmacy Practice and
Pharmacy Administration
Philadelphia College of Pharmacy and Science
Philadelphia, Pennsylvania

James M. McKenney, PharmD
Professor and Chairman
Division of Clinical Pharmacy
Department of Pharmacy and Pharmaceutics
School of Pharmacy
Virginia Commonwealth University
Richmond, Virginia

Nicolaas Otten, PharmD
Coordinator, Pharmaceutical Assessment
Canadian Center of Health Technology Assessment
Ottawa, Ontario, Canada

Daniel J. Rader, MD
Assistant Professor of Medicine
Division of Cardiovascular Medicine
University of Pennsylvania Medical Center
Director, Preventive Cardiology and
Lipid Research Center
University of Pennsylvania Health System
Philadelphia, Pennsylvania

James Shepherd, MD, PhD, FRCP
Professor of Pathological Biochemistry
Clinical Director of Laboratory Services
Glasgow Royal Infirmary
Glasgow University
Glasgow, Scotland

Sidney C. Smith, Jr., MD
Professor of Medicine
Chief, Division of Cardiology
Director, Center for Cardiovascular Disease
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Evan A. Stein, MD, PhD, FRCPC, FCAP
President
Medical Research Laboratories
Highland Heights, Kentucky

J. Russell Teagarden
Vice President, Clinical Practices & Therapeutics
Merck-Medco Managed Care, L.L.C.
Montvale, New Jersey

DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty participating in programs sponsored by corporate organizations to disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations.

- **Susan Andrade, ScD**
Grant/Research Support From:
Merck
Lecturer For:
Merck
- **John S. Banas, Jr., MD, FACC**
Lecturer For:
Bristol-Myers Squibb
Merck
Warner Lambert
Parke-Davis
- **James C. Bonnette, MD**
Grant/Research Support From:
Parke-Davis
- **W. Virgil Brown, MD**
Grant/Research Support From, Consultant For,
and Lecturer For:
Bristol-Myers Squibb
Merck
Warner Lambert
Parke-Davis
KOS Pharmaceuticals
Pfizer
Novartis
Bayer

(Disclosures continued on following page)

-
- **Stuart M. Cobbe, MD, FRCP**
Grant/Research Support From:
Bristol-Myers Squibb
Lecturer and Consultant For:
Bristol-Myers Squibb
 - **Peter Davey, MD, FRCP**
Grant/Research Support From:
Bristol-Myers Squibb
Bayer
 - **Bruce Kinosian, MD**
Grant/Research Support From:
Merck
 - **Grant D. Lawless, MD, RPh**
Lecturer For:
Bristol-Myers Squibb
 - **William F. McGhan, PharmD, PhD**
Consultant For:
Bristol-Myers Squibb
Merck
Novartis
 - **James M. McKenney, PharmD**
Grant/Research Support From:
Pfizer
Parke-Davis
Merck
Novartis
Bristol-Myers Squibb
Bayer
SmithKline Beecham
Merck
Lecturer For:
Bristol-Myers Squibb
Parke-Davis
Pfizer
SmithKline Beecham
Merck
 - **James Shepherd, MD, PhD, FRCP**
Consultant For:
Bristol-Myers Squibb

The participants listed below declare no financial arrangements or affiliations with any corporate organization or with any corporate organization whose products may be mentioned in this presentation.

- **Paul C. Langley, PhD**
- **Simeon Margolis, MD, PhD**
- **Nicolaas Otten, PharmD**
- **Daniel J. Rader, MD**